Zusammenfassung
Vor 25 Jahren berichtete die Forschergruppe um den kanadischen Psychiater de Montigny erstmals von der erfolgreichen Behandlung bis dahin therapierefraktärer depressiver Patienten durch die Addition von Lithium zum Antidepressivum. Bei der 1981 publizierten Arbeit handelte es sich um eine offene, unkontrollierte Beobachtung an lediglich 8 Patienten, die modernen methodischen Standards nicht genügt. Dennoch hat dieses in der Folge als „Lithiumaugmentation“ bezeichnete Behandlungsverfahren die Strategien zur Pharmakotherapie depressiver Erkrankungen nachhaltig verändert. Bemerkenswert ist auch die Vorgeschichte: De Montigny und Kollegen waren strikt theoriegeleitet zu der Idee der Lithiumaugmentation gelangt, nachdem sie in tierexperimentellen Vorarbeiten in den 1970er Jahren gefunden hatten, dass eine mehrwöchige Antidepressivavorbehandlung zu einer Sensibilisierung von zentralnervösen Serotoninrezeptoren führt. Die bekannten proserotonergen Eigenschaften des bereits seit 1949 systematisch als Psychopharmakon eingesetzten Lithiums sollten zur Stimulation dieser Rezeptoren genutzt werden. In den 1980er und 1990er Jahren belegten dann zahlreiche zunächst offene, später einfach- und doppelblinde randomisierte und plazebokontrollierte Studien die Wirksamkeit der Lithiumaugmentation. Untersuchungen zur Optimierung der klinischen Anwendung ergaben Ende der 1990er Jahre, dass eine Lithiumaugmentation bis zur Beurteilung ihrer Wirksamkeit über ca. 2 Wochen unter Ziel-Lithiumserumspiegeln, wie sie auch zur Phasenprophylaxe etabliert sind, durchgeführt und im Fall der Response für 6–12 Monate im Sinne einer Erhaltungstherapie fortgeführt werden sollte. Gegenwärtig werden die noch nicht vollständig aufgeklärten Wirkmechanismen der Lithiumaugmentation untersucht. Aktuelle Ergebnisse zeigen, dass neben der von de Montigny postulierten Idee auch eine aktivierende Wirkung auf das Stresshormonsystem eine Rolle spielen könnte. Aufgrund der guten Evidenzlage ist die Lithiumaugmentation heute ein in gängigen Leitlinien und Therapiealgorithmen bei Nonresponse auf eine Antidepressivamonotherapie empfohlenes Behandlungsverfahren.
Summary
Twenty-five years ago the research group of the Canadian psychiatrist de Montigny reported treating antidepressant-refractory depressive patients successfully by adding lithium to their antidepressant. The report, published in 1981 as an open-label uncontrolled observation of only eight patients, falls short of today’s methodological standards, but the treatment method, subsequently known as lithium augmentation, nonetheless was to change profoundly the pharmacological strategies for depressive disorders. The story of its development is remarkable, starting with a strictly theoretical idea conceived by Montigny and his colleagues after animal experiments in the 1970s had revealed that pretreatment with an antidepressant over several weeks led to sensitization of central nervous serotonin receptors. The team postulated that the proserotonergic characteristics of lithium, which had been systematically used as a psychotropic drug since 1949, could thus be used specifically to stimulate these receptors. Lithium augmentation demonstrated its effectiveness in the 1980s and 1990s, first in open-label and later in randomized and placebo-controlled studies. In the late 1990s studies aimed at optimizing its clinical application indicated that lithium augmentation must be administered for at least 2 weeks, with lithium serum levels within the range established for prophylactic treatment and assuming patient response, and that the combination of lithium and antidepressant must be continued as a maintenance therapy for 6 to 12 months. Research has yet to clarify how lithium augmentation actually works. Current results show that in addition to the idea postulated by Montigny, lithium could also have an activating effect on the cortisol axis. Thanks to the sound body of evidence which has accrued in the meantime, lithium augmentation is recommended in most guidelines and treatment algorithms as a main strategy for patients who do not respond to antidepressant monotherapy.
Literatur
Adli M, Bauer M, Rush AJ (2006) Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 59: 1029–1038
Adli M, Berghöfer A, Linden M et al. (2002) Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders – results of a two-year observational study. J Clin Psychiatry 63: 782–790
Adli M, Bschor T, Canata B et al. (1998) Lithium in the treatment of acute depression. Fortschr Neurol Psychiatr 66: 435–441
Adli M, Rush AJ, Möller HJ, Bauer M (2003) Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry [Suppl 3] 36: 222–229
Adli M, Wiethoff K, Baghai T, Bauer M (2005) Algorithmusgestützte Behandlung stationärer Patienten mit depressiven Erkrankungen: das Berliner Algorithmusprojekt. In: Bauer M, Berghöfer A, Adli M (Hrsg) Therapieresistente Depressionen. Springer Medizin, Heidelberg, S 477–487
Adli M, Wiethoff K, Baghai TC et al. (2005) Evaluating algorithm-guided treatment for depression: The German Algorithm Project (GAP) [Abstract]. Pharmacopsychiatry 38: A002
Álvarez E, Pérez-Solá V, Pérez-Blanco J et al. (1997) Predicting outcome of lithium added to antidepressants in resistant depression. J Affect Disord 42: 179–186
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (Hrsg) (2006) Empfehlungen zur Therapie der Depression. 2. Aufl. Arzneiverordnung in der Praxis, 33, Sonderheft 1
Bauer M, Bschor T, Kunz D et al. (2000) Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 157: 1429–1435
Bauer M, Crossley NA, Gerber S, Bschor T (2006) The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in neuropsychiatry. The comprehensive guide. Informa healthcare, London, pp 109–127
Bauer M, Döpfmer S (1999) Lithium augmentation in treatment-resistant depression – A meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427–434
Bauer M, Trendelenburg M, Bschor T (2005) Augmentationsbehandlung mit Lithium. In: Bauer M, Berghöfer A, Adli M (Hrsg) Akute und therapieresistente Depressionen. Springer Medizin Verlag, Heidelberg, S 229–242
Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biol Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatr 3: 5–43
Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biol Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatr 3: 69–86
Baumann P, Nil R, Souche A et al. (1996) A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16: 307–314
Browne M, Lapierre YD, Hrdina PD, Horn E (1990) Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol 5: 103–110
Bschor T (2005) Depression. In: Linden M, Müller WE (Hrsg) Rehabilitations-Psychopharmakotherapie. Deutscher Ärzte-Verlag, Köln, S 227–251
Bschor T, Adli M, Baethge C et al. (2002) Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 27: 470–478
Bschor T, Baethge C, Adli M et al. (2003) Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiat Res 37: 135–143
Bschor T, Baethge C, Adli M et al. (2003) Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety 17: 43–48
Bschor T, Bauer M (2004) Is successful lithium augmentation limited to serotonergic antidepressants? [Brief]. J Clin Psychopharmacol 24: 240–241
Bschor T, Bauer M (2004) Therapieresistente Depressionen. In: Lemke RM (Hrsg) Affektive Störungen. Thieme Verlag, Stuttgart, S 101–115
Bschor T, Bauer M (2006) Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 12: 2985–2992
Bschor T, Berghöfer A, Ströhle A et al. (2002) How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 22: 427–430
Bschor T, Canata B, Müller-Oerlinghausen B, Bauer M (2001) Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 64: 261–265
Bschor T, Lewitzka U, Bauer M (2003) Lithiumaugmentation zur Behandlung der bipolaren Depression. Psychoneuro 29: 392–399
Burgess S, Geddes J, Hawton K et al. (eds) (2002) Lithium for maintenance treatment of mood disorders (Cochrane Review). In: The Cochrane Library, Issue 3, Oxford, Update Software
Cade JFJ (1949) Lithium salts in the treatment of psychotic-excitement. Med J Aust 36: 349–352
Chaput Y, De Montigny C, Blier P (1991) Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5: 219–229
Christodoulou GN, Lykouras EP (1982) Abrupt lithium discontinuation in manic- depressive patients. Acta Psychiatr Scand 65: 310–314
Cowen PJ, McCance SL, Ware CJ et al. (1991) Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 159: 341–346
De Montigny C (1991) Lithium addition in treatment-resistant depression: evidence for the involvement of the serotonin system. In: Racagni G, Brunello N, Fukuda T (eds) Biol Psychiatry. Volume 1. Elsevier Science Publishers B.V., Amsterdam, pp 243–244
De Montigny C, Aghajanian GK (1978) Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202: 1303–1306
De Montigny C, Cournoyer G, Morisette R (1983) Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antideoressant drugs and lithium on the serotonin system. Arch Gen Psychiatry 40: 1327–1334
De Montigny C, Elie R, Caille G (1985) Rapid response to the addition of lithium in iprindole-resistant unipolar depression: a pilot study. Am J Psychiatry 142: 220–223
De Montigny C, Grunberg F, Mayer A, Deschenes JP (1981) Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 138: 252–256
Delgado PL, Price LH, Charney DS Heninger GR (1988) Efficacy of fluvoxamine in treatment refractory depression. J Affect Disord 15: 55–60
Dinan TG (1993) Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 88: 300–301
Dinan TG, Barry S (1989) A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders. Acta Psychiatr Scand 80: 97–100
Fava M, Alpert J, Nierenberg A et al. (2002) Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 22: 379–387
Fava M, Rosenbaum JF, McGrath PJ et al. (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151: 1372–1374
Felber W (1987) Die Lithiumprophylaxe der Depression vor 100 Jahren – ein genialer Irrtum. Fortschr Neurol Psychiatr 55: 141–144
Flint AJ, Rifat SL (1994) A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J Clin Psychopharmacol 14: 353–356
Fontaine R, Ontiverod A, Elie R, Vézina M (1991) Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. Biol Psychiatry 29: 946–948
Hawley CJ, Roberts AG, Baldwin DS (1994) Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions. Int Clin Psychopharmacol 9: 31–33
Hawley CJ, Roberts AG, Walker MH (1994) Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions. Int Clin Psychopharmacol 8: 266–267
Heninger GR, Charney DS, Sternberg DE (1983) Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 40: 1335–1342
Heuser IJE, Schweiger U, Gotthardt U et al. (1996) Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 153: 93–99
Hoencamp E, Haffmans PMJ, Dijken WA (1994) Brofaromine versus lithium addition to maprotiline: a double blind study in maprotiline refractory depressed outpatients. J Affect Disord 30: 219–227
Hoencamp E, Haffmans PMJ, Dijken WA, Huijbrechts I (2000) Lithium augmentation of venlafaxine: an open-label trial. J Clin Psychiatry 20: 538–543
Holsboer-Trachsler E, Hemmeter U, Hatzinger M et al. (1994) Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment-neurobiological and psychometric assessment of course. J Psychiatr Res 28: 381–399
Joffe RT, Levitt AJ, Bagby RM et al. (1993) Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 163: 574–578
Joffe RT, Singer W, Levitt AJ, MacDonald C (1993) A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50: 387–393
Juckel G, Mavrogiorgou P (2006) Interaction of lithium with neurotransmitter systems: serotonin and others. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in neuropsychiatry. The comprehensive guide. Informa healthcare, London, pp 329–340
Kantor D, McNevin S, Leichner P et al. (1986) The benefit of lithium carbonate adjunct in refractory depression – fact or fiction? Can J Psychiatry 31: 416–418
Katona CLE, Abou-Saleh MT, Harrison DA et al. (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166: 80–86
Lange C (ed) (1886) Om periodiske Depressionstilstande og deres Patogenese. Jacob Lunds Forlag, Kopenhagen
Linden M, Helmchen H, Mackert A, Müller-Oerlinghausen B (1994) Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed inpatients. Pharmacopsychiatry 27 [Suppl]: 51–53
McCance-Katz E, Price LH, Charney DS, Heninger GR (1992) Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 108: 93–97
Nelson JC (1998) Overcoming treatment resistance in depression. J Clin Psychiatry [Suppl 16] 59: 13–19
Nemeroff CB (1996) Augmentation strategies in patients with refractory depression. Depress Anxiety 4: 169–181
Nierenberg AA, Papakostas GI, Petersen T et al. (2003) Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 23: 92–95
Platman SR, Fieve RR (1968) Lithium carbonate and plasma cortisol response in the affective disorders. Arch Gen Psychiatry 18: 591–594
Platman SR, Hilton JG, Koss MC, Kelly WG (1971) Production of cortisol in patients with manic-depressive psychosis treated with lithium carbonate. Dis Nerv Syst 32: 542–544
Price LH, Carpenter LL, Rasmussen SA (2001) Drug combination strategies. In: Amsterdam JD, Hornig M, Nierenberg AA (eds) Treatment-resistant mood disorders. Univ Press, Cambridge, pp 194–222
Price LH, Charney DS, Delgado PL et al. (1990) Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry 14: 459–472
Price LH, Charney DS, Henninger GR (1986) Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 143: 1387–1392
Reisine T, Zatz M (1987) Interactions among lithium, calcium, diacylglycerides, and phorbolesters in the regulation of adrenocorticotropin hormone release from AtT-20 cells. J Neurochem 49: 884–889
Rybakowski J, Matkowski K (1992) Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. Eur Neuropsychopharmacol 2: 161–165
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. J Neuropsychiatry Clin Neurosci 7: 524–533
Schöpf J, Baumann P, Lemarchand T, Rey M (1989) Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 22: 183–187
Sluzeska A, Sobieska M, Rybakowski JK (1997) Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Biol Psychiatry 35: 123–127
Souza FG, Goodwin GM (1991) Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 158: 666–675
Stein G, Bernadt M (1993) Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 162: 634–640
Sugawara M, Hashimoto K, Hattori T et al. (1988) Effects of lithium on the hypothalamo-pituitary-adrenal axis. Endocrinol Jpn 35: 655–663
Uehlinger C, Nil R, Amey M et al. (1995) Citalopram-lithium combination treatment of elderly depressed patients: a pilot study. Int J Ger Psychiatry 10: 281–287
Zatz M, Reisine TD (1985) Lithium induces corticotropin secretion and desensitization in cultured anterior pituitary cells. Proc Natl Acad Sci U S A 82: 1286–1290
Zusky PM, Biederman J, Rosenbaum JF et al. (1988) Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 8: 120–124
Interessenkonflikt
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bschor, T., Lewitzka, U., Pfennig, A. et al. Fünfundzwanzig Jahre Lithiumaugmentation. Nervenarzt 78, 1237–1247 (2007). https://doi.org/10.1007/s00115-007-2273-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-007-2273-5